Theman T A, Collins M T
Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, 30 Convent Drive, Bethesda, MD 20892, USA.
Curr Pharm Biotechnol. 2009 Apr;10(3):289-301. doi: 10.2174/138920109787847538.
Bone cells, particularly osteoblasts and osteoclasts, exhibit functional responses to calcium (Ca(2+)). The identification of the calcium-sensing receptor (CaR) in parathyroid glands as the master regulator of parathyroid hormone (PTH) secretion proved that cells could specifically respond to changes in divalent cation concentration. Yet, after many years of study, it remains unclear whether this receptor, which has also been identified in bone, has functional import there. Various knockout and transgenic mouse models have been developed, but conclusions about skeletal phenotypes remain elusive. Complex endocrine feedback loops involving calcium, phosphorus, vitamin D, and PTH confound efforts to isolate the effects of a single mineral, hormone, or receptor and most models fail to account for other local factors such as parathyroid hormone related protein (PTHrP). We review the relevant mouse models and discuss the importance of CaR in chondrogenesis and osteogenesis. We present the evidence for a non-redundant role for CaR in skeletal mineralization, including our experience in patients with activating CaR mutations. Additionally, we review emerging research on the importance of the CaR to the regulation of serum calcium homeostasis independent of PTH, the role of the CaR in the hematopoietic stem cell niche with implications for bone marrow transplant, and early evidence that implies a role for the CaR as a factor in skeletal metastasis from breast and prostate cancer. We conclude with a discussion of drugs that target the CaR directly either as agonists (calcimimetics) or antagonists (calcilytics), and the consequences for bone physiology and pathology.
骨细胞,尤其是成骨细胞和破骨细胞,对钙(Ca(2+))表现出功能反应。甲状旁腺中钙敏感受体(CaR)作为甲状旁腺激素(PTH)分泌的主要调节因子的鉴定证明,细胞能够特异性地对二价阳离子浓度的变化作出反应。然而,经过多年研究,目前仍不清楚这种在骨中也已被鉴定出的受体在骨中是否具有功能重要性。已经开发了各种基因敲除和转基因小鼠模型,但关于骨骼表型的结论仍然难以捉摸。涉及钙、磷、维生素D和PTH的复杂内分泌反馈回路使分离单一矿物质、激素或受体的作用的努力变得复杂,并且大多数模型未能考虑其他局部因素,如甲状旁腺激素相关蛋白(PTHrP)。我们综述了相关的小鼠模型,并讨论了CaR在软骨生成和成骨中的重要性。我们提供了CaR在骨骼矿化中具有非冗余作用的证据,包括我们在具有激活CaR突变的患者中的经验。此外,我们综述了关于CaR在独立于PTH调节血清钙稳态中的重要性的新兴研究、CaR在造血干细胞龛中的作用及其对骨髓移植的影响,以及暗示CaR作为乳腺癌和前列腺癌骨骼转移因素的早期证据。我们最后讨论了直接靶向CaR的药物,即激动剂(拟钙剂)或拮抗剂(钙解剂),以及它们对骨生理学和病理学的影响。